Psychedelics and substance use disorder treatment.
Caitlin M. DuPont, Matthew W. Johnson
International review of neurobiology 2025 DOI: 10.1016/bs.irn.2025.03.005 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | LSD psilocybin ayahuasca |
| Topics | Addiction Ayahuasca LSD Psilocybin |
| Keywords | Psychedelics Substance use disorders Tobacco use disorder Psychedelic substances: hallucinogens Addiction disorders: addiction Therapeutic approaches: treating Reduce drinking Achieve abstinence Improving brain function Fostering personal insights |
| Citations | 6 |
| Key findings | Classic psychedelics appear beneficial for alcohol, tobacco, and opioid use disorders, but no trials exist for stimulant or cannabis use disorders, suggesting potential broad transdiagnostic efficacy. |
Abstract
The current chapter presents the literature evaluating the effects of classic psychedelic treatments on five substance use disorders: alcohol, tobacco, opioid, stimulant, and cannabis. Most work on psychedelics and substance use disorders was conducted for alcohol use disorder. A range of classic psychedelics (LSD, psilocybin, and ayahuasca) appear to be beneficial for facilitating both reduced drinking and abstinence. Small clinical trials have also shown promising initial results for both tobacco and opioid use disorders. In contrast, no trials have yet been conducted for stimulant and cannabis use disorders. Furthermore, the majority of studies described are naturalistic observational studies or correlational survey data. However, if such observational studies reflect causal therapeutic potential, these studies, combined with clinical trials, suggest potential broad transdiagnostic efficacy of psychedelics across multiple addictive drugs. The transdiagnostic effects of psychedelics are likely due to a combination of biological and psychological factors. Biologically, psychedelics appear to ameliorate deficits in brain areas involved in reward and emotional processing, which may reduce the risk of relapse. Psychologically, the insights gained during a psychedelic experience may reinforce personal motivations for sobriety and support subsequent behavior change. Overall, more work is needed to better characterize the potential benefits and limitations of psychedelic treatment for substance use disorders.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Argues classic psychedelics including ayahuasca appear beneficial for alcohol, tobacco, and opioid use disorders, with no trials yet for stimulant or cannabis use disorders, and most evidence is observational.
Synthesized
Comparable studies
Other narrative reviews on ayahuasca for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness | 2018 | Review | |
| Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatment | 2012 | Review | |
| The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges | 2021 | Review | |
| Can psychedelic compounds play a part in drug dependence therapy? Patients with substance dependency | 2015 | Review | |
| Advances in Psychedelic Medicine | 2019 | Review |
Citations in the library
Cited by 6
- Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders. Journal of Psychoactive Drugs November 10, 2025
- Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex. European Journal of Neuroscience June 1, 2026
- Psilocybin decreases reward-seeking behavior accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex bioRxiv (Cold Spring Harbor Laboratory) December 26, 2025
- Psychedelics in Psychiatry: New Treatment Paradigms or Addictive Treatment Strategies? A Narrative Review Pharmaceutical Science December 9, 2025
- Ayahuasca prevents the reinstatement of cocaine-induced rewarding effects in C57Bl/6 mice. Psychopharmacology October 31, 2025
and 1 more in the library
Cites 54
- Default Mode Network Activity and Connectivity in Psychopathology Annual Review of Clinical Psychology March 29, 2012
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- 20 years of the default mode network: A review and synthesis Neuron May 10, 2023
and 49 more in the library